Aura Biosciences, Inc.

NasdaqGM:AURA 株式レポート

時価総額：US$685.0m

Aura Biosciences マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Natalie Holles

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権n/a
経営陣の平均在職期間2.2yrs
取締役会の平均在任期間5.2yrs

経営陣の近況

Recent updates

分析記事 • Nov 26

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 15

Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer

Summary Aura Biosciences has continued its long work on bel-sar in cancers of the eye, bringing to bear some very interesting signals. While they have sufficient funding for now, their own timelines to a phase 3 readout suggest they will face a cash crisis well in advance of topline, pivotal data. I am upgrading AURA stock to a "hold" sentiment based on a more favorable timeline, but not a buy due to severe risks of failure of their trials. Read the full article on Seeking Alpha
分析記事 • May 03

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jan 11

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 17

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Summary Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies. Despite minor cash risks, Aura's strong data, unmet medical need focus, and solid execution make it a compelling biotech investment. Read the full article on Seeking Alpha
分析記事 • Sep 11

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Oct 03

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Mar 28

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Oct 01

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences (NASDAQ:AURA) is trading higher in the morning hours Tuesday after JMP Securities issued an Outperform rating as it started coverage on the clinical-stage biotech citing its novel therapeutic platform. The virus-like drug conjugates (VDC) platform Aura (AURA) is advancing “could establish a new standard of care in multiple cancer indications,” the analyst Jonathan Wolleben wrote with an DCF-derived price target of $26 per share for the stock. The firm highlights Aura’s (AURA) VDC candidate, AU-011, which is undergoing studies for choroidal melanoma, the commonest primary ocular cancer in adults, according to the analyst. In addition, JMP notes that Phase 2 data expected in the fall for AU-011 should de-risk the pivotal trial for the candidate scheduled to start later this year. In March, Aura (AURA) announced that the European Commission issued orphan drug designation for AU-011 as a treatment for several conditions of uveal melanoma, including choroidal melanoma.
Seeking Alpha • Jun 30

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' (NASDAQ:AURA) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate, which it is developing for multiple oncology indications. "This milestone supports our goal to advance the development of belzupacap sarotalocan for patients with NMIBC in need of better and earlier targeted treatment options with the potential to help preserve the bladder," said Cadmus Rich, chief medical officer and head of R&D, Aura. The company said its phase 1 trial of AU-011 in this indication is expected to begin in H2 2022, with initial data expected in 2023. AURA +3.02% to $12.95 premarket June 30
分析記事 • Apr 10

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Natalie Holles (53 yo)

less than a year
在職期間

Ms. Natalie C. Holles is Independent Director of LeonaBio, Inc. from May 5, 2026. Ms. Natalie C. Holles is President, CEO & Director of Aura Biosciences, Inc. from April 30, 2026. Ms. Holles served as Chie...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Anthony Gibney
Chief Financial & Business Officer1.1yrsUS$2.82m0.052%
$ 353.6k
Jill Hopkins
Chief Medical Officer & President of Research and Development2.7yrsUS$2.19m0.054%
$ 372.9k
Natalie Holles
Presidentless than a yearデータなしデータなし
Amy Elazzouzi
Interim Principal Accounting Officer1.8yrsデータなし0.11%
$ 745.6k
Mark Plavsic
Chief Technology Officer2.8yrsデータなし0.22%
$ 1.5m
Conor Kilroy
Chief Legal Officer & Secretary2.2yrsUS$2.13m0.036%
$ 246.2k
Patrick Nealon
Senior Vice President of Clinical Development Operations3.4yrsデータなしデータなし
Anthony Daniels
VP & Therapeutic Area of Head Ocular Oncology3.4yrsデータなしデータなし
Joe McQuaid
VP & Therapeutic Area Head of Urologic Oncologyless than a yearデータなしデータなし
2.2yrs
平均在職期間
54yo
平均年齢

経験豊富な経営陣: AURAの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Natalie Holles
Presidentless than a yearデータなしデータなし
Evangelos Gragoudas
Scientific & Clinical Advisorno dataデータなしデータなし
Sapna Srivastava
Independent Director5.1yrsUS$213.27k0.0095%
$ 65.2k
Jay Duker
Scientific & Clinical Advisorno dataデータなしデータなし
Antony Mattessich
Independent Director4.8yrsUS$214.89k0.0095%
$ 65.2k
Giovanni Mariggi
Independent Director7.2yrsデータなしデータなし
Richard Carvajal
Scientific & Clinical Advisorno dataデータなしデータなし
David Johnson
Independent Chairman of the Board5.4yrsUS$235.33k0.28%
$ 1.9m
Arun Singh
Scientific & Clinical Advisorno dataデータなしデータなし
Carol Shields
Scientific & Clinical Advisorno dataデータなしデータなし
Brian Marr
Scientific & Clinical Advisorno dataデータなしデータなし
Karan Takhar
Independent Director5.3yrsデータなしデータなし
5.2yrs
平均在職期間
55yo
平均年齢

経験豊富なボード: AURAの 取締役会 は 経験豊富 であると考えられます ( 5.2年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/12 21:45
終値2026/06/12 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Aura Biosciences, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6

アナリスト機関
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Edward WhiteH.C. Wainwright & Co.